{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:10:53Z","timestamp":1790118653172,"version":"4.0.1"},"reference-count":44,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            AmBisome is a liposomal formulation of amphotericin B that has broad-spectrum antifungal activity and greatly reduced toxicity compared to the parent drug. In this study, amphotericin B deoxycholate (Fungizone) (1 mg\/kg) and AmBisome (1 to 20 mg\/kg) were tested as single-dose prophylactic agents in both immunocompetent and immunosuppressed C57BL\/6 mice challenged with either\n            <jats:italic>Candida albicans<\/jats:italic>\n            or\n            <jats:italic>Histoplasma capsulatum<\/jats:italic>\n            . Prophylactic efficacy was based on survival and fungal burden in the target organ (kidneys or spleen). At 9 to 10 days after histoplasma challenge, 80 to 90% of both immunocompetent and immunosuppressed mice in the control and Fungizone groups had died. All AmBisome-treated mice survived, although in the AmBisome groups given 1 mg\/kg, the mice became moribund by day 10 to 12. No spleen CFU were detected in the histoplasma-challenged mice given 10 or 20 mg of AmBisome per kg. By 23 to 24 days after histoplasma challenge, fungal growth and\/or death had occurred in all immunosuppressed mice except for four mice receiving 20 mg of AmBisome per kg. There were still no detectable fungi in the spleens of immunocompetent mice given 10 or 20 mg of AmBisome per kg. In the\n            <jats:italic>C. albicans<\/jats:italic>\n            experiment at 7 days postchallenge, all animals in both untreated and treated groups were alive with culture-positive kidneys. The kidney fungal burdens in AmBisome groups given 5 to 20 mg\/kg were at least 1 log unit lower than those in the Fungizone group and significantly lower than those in the untreated control group (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05). There was a trend toward decreasing fungal growth in the kidneys as the dose of AmBisome was increased. In conclusion, these results show that a single high dose of AmBisome (5 to 20 mg\/kg) had prophylactic efficacy in immunocompetent and immunosuppressed murine\n            <jats:italic>H. capsulatum<\/jats:italic>\n            and\n            <jats:italic>C. albicans<\/jats:italic>\n            models.\n          <\/jats:p>","DOI":"10.1128\/aac.44.9.2327-2332.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"2327-2332","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["Single-Dose AmBisome (Liposomal Amphotericin B) as Prophylaxis for Murine Systemic Candidiasis and Histoplasmosis"],"prefix":"10.1128","volume":"44","author":[{"given":"April","family":"Garcia","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->California State Polytechnic University, Pomona, California 91768,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill P.","family":"Adler-Moore","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->California State Polytechnic University, Pomona, California 91768,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Proffitt","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->NeXstar Pharmaceuticals, Inc., San Dimas, California 917732"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","first-page":"S3","article-title":"AmBisome targeting to fungal infections.","volume":"14","author":"Adler-Moore J.","year":"1994","unstructured":"Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant. 14 (Suppl. 5) 1994 S3 S7","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/08982109309150729"},{"key":"e_1_3_1_4_2","unstructured":"Adler-Moore\n              J. P.\n              Proffitt\n              R. T.\n          AmBisome: a developmental case study of a liposomal formulation of the antifungal agent amphotericin B.\n          Injectable dispersed systems: formulation processing and performance in press.\n              Burgess\n              D.\n              Stout\n              P. J.\n          2000\n          Marcel Dekker Inc.\n          New York N.Y"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2042"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.10.1560"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/clinids\/22.3.462","article-title":"Failure of systemic empirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer.","volume":"22","author":"Blumberg E. A.","year":"1996","unstructured":"Blumberg E. A. Reboli A. C. Failure of systemic empirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer. Clin. Infect. Dis. 22 1996 462 466","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01967060"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/1097-0142(19940415)73:8<2099::AID-CNCR2820730814>3.0.CO;2-N","article-title":"Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B.","volume":"73","author":"Bodey G. P.","year":"1994","unstructured":"Bodey G. P. Anaissie E. J. Elting L. S. Estey E. O'Brien S. Kantarjian H. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 73 1994 2099 2106","journal-title":"Cancer"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.263"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.1365-2567.1999.00835.x","article-title":"Different effects of granulocyte colony-stimulating factor or bacterial infection on bone-marrow cells of cyclophosphamide-treated or irradiated mice.","volume":"97","author":"Buisman A. M.","year":"1999","unstructured":"Buisman A. M. Van Zwet T. L. Langermans J. A. Geertsma M. F. Leenen P. J. van Furth R. Different effects of granulocyte colony-stimulating factor or bacterial infection on bone-marrow cells of cyclophosphamide-treated or irradiated mice. Immunology 97 1999 601 610","journal-title":"Immunology"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00003495-199855040-00008","article-title":"Liposomal amphotericin B: therapeutic use in the management of fungal infections and visceral leishmaniasis.","volume":"55","author":"Coukell A. J.","year":"1998","unstructured":"Coukell A. J. Brogden R. N. Liposomal amphotericin B: therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 55 1998 585 612","journal-title":"Drugs"},{"key":"e_1_3_1_13_2","unstructured":"Daniel\n              W.\n          Biostatistics: a foundation for analysis in the health sciences.\n          1991\n          John Wiley and Sons Inc.\n          New York N.Y"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199203263261301"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.bmt.1701866","article-title":"Blood and marrow transplantation activity in Europe 1997.","volume":"24","author":"Gratwohl A.","year":"1999","unstructured":"Gratwohl A. Passweg J. Baldomero H. Hermans J. Blood and marrow transplantation activity in Europe 1997. Bone Marrow Transplant. 24 1999 231 245","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.2.408-410.2000"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/clinids\/7.5.619","article-title":"Empiric amphotericin B therapy in patients with acute leukemia.","volume":"7","author":"Holleran W. M.","year":"1985","unstructured":"Holleran W. M. Wilbur J. R. DeGregorio M. W. Empiric amphotericin B therapy in patients with acute leukemia. Rev. Infect. Dis. 7 1985 619 624","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ajcp\/86.4.518","article-title":"The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary Aspergillus.","volume":"86","author":"Kahn F. W.","year":"1986","unstructured":"Kahn F. W. Jones J. M. England D. M. The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary Aspergillus. Am. J. Clin. Pathol. 86 1986 518 523","journal-title":"Am. J. Clin. Pathol."},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bmt.1701543","article-title":"Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.","volume":"23","author":"Kelsey S. M.","year":"1999","unstructured":"Kelsey S. M. Goldman J. M. McCann S. Newland A. C. Scarffe J. H. Oppenheim B. A. Mufti G. J. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant. 23 1999 163 168","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<291::AID-CNCR13>3.0.CO;2-O","article-title":"Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia. Results of a prospective randomized phase III study.","volume":"83","author":"Kern W.","year":"1998","unstructured":"Kern W. Behre G. Rudolf T. Kerkhoff A. Grote-Metke A. Eimermacher H. Kubica U. Wormann B. Buchner T. Hiddemann W. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia. Results of a prospective randomized phase III study. Cancer 83 1998 291 301","journal-title":"Cancer"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000239591","article-title":"Breakthrough fungemia appearing during empiric therapy with amphotericin B.","volume":"43","author":"Krcmery V.","year":"1997","unstructured":"Krcmery V. Jr. Spanik S. Kunova A. Trupl J. Breakthrough fungemia appearing during empiric therapy with amphotericin B. Chemotherapy 43 1997 367 370","journal-title":"Chemotherapy"},{"key":"e_1_3_1_22_2","unstructured":"Kuo\n              J.\n              Fox\n              E.\n              McDonald\n              S.\n          SigmaStat statistical software for working scientists\u2014users manual.\n          1992\n          Jandel Scientific\n          San Rafael Calif"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.10.3.477"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/00003495-199244010-00002","article-title":"Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.","volume":"44","author":"Lyman C. A.","year":"1992","unstructured":"Lyman C. A. Walsh T. J. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44 1992 9 35","journal-title":"Drugs"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0378-4347(00)84430-8","article-title":"An internally-standardized assay for amphotericin B in tissues and plasma.","volume":"274","author":"Mayhew J.","year":"1983","unstructured":"Mayhew J. Fiore C. Murray T. Barza M. An internally-standardized assay for amphotericin B in tissues and plasma. J. Chromatogr. 274 1983 271 279","journal-title":"J. Chromatogr."},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/515129","article-title":"Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial.","volume":"28","author":"Menichetti F.","year":"1999","unstructured":"Menichetti F. Del Favero A. Martino P. Bucaneve G. Micozzi A. Girmenia C. Barbabietola G. Pagano L. Leoni P. Specchia G. Caiozzo A. Raimondi R. Mandelli F. the GIMEMA Infection Program Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin. Infect. Dis. 28 1999 250 255","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1365-2141.1999.01465.x","article-title":"A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies.","volume":"105","author":"Morgenstern G. R.","year":"1999","unstructured":"Morgenstern G. R. Prentice A. G. Prentice H. G. Ropner J. E. Schey S. A. Warnock D. A. the U.K. Multicentre Antifungal Prophylaxis Study Group A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br. J. Haematol. 105 1999 901 911","journal-title":"Br. J. Haematol."},{"key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/infdis\/165.5.891","article-title":"Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients.","volume":"165","author":"Perfect J. R.","year":"1992","unstructured":"Perfect J. R. Klotman M. E. Gilbert C. C. Crawford D. D. Rosner G. L. Wright K. A. Peters W. P. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J. Infect. Dis. 165 1992 891 897","journal-title":"J. Infect. Dis."},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","article-title":"Management of fever in patients with cancer and treatment-induced neutropenia.","volume":"328","author":"Pizzo P. A.","year":"1993","unstructured":"Pizzo P. A. Management of fever in patients with cancer and treatment-induced neutropenia. N. Engl. J. Med. 328 1993 1323 1332","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.","volume":"98","author":"Prentice H. G.","year":"1997","unstructured":"Prentice H. G. Hann I. M. Herbrecht R. Aoun M. Kvaloy S. Catovsky D. Pinkerton C. R. Schey S. A. Jacobs F. Oakhill A. Stevens R. F. Darbyshire P. J. Gibson B. E. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 98 1997 711 718","journal-title":"Br. J. Haematol."},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/28.suppl_B.49","article-title":"Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents.","volume":"28","author":"Proffitt R. T.","year":"1991","unstructured":"Proffitt R. T. Satorius A. Chiang S.-M. Sullivan L. Adler-Moore J. P. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28 (Suppl. B) 1991 49 62","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0002-9343(94)90345-X","article-title":"The prophylactic use of low-dose amphotericin B in bone marrow transplant patients.","volume":"97","author":"Riley D. K.","year":"1994","unstructured":"Riley D. K. Pavia A. T. Beatty P. G. Petersen F. B. Spruance J. L. Stokes R. Evans T. G. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am. J. Med. 97 1994 509 514","journal-title":"Am. J. Med."},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.6.1545"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/02681219880000221","article-title":"Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells.","volume":"36","author":"Sperry P. J.","year":"1998","unstructured":"Sperry P. J. Cua D. J. Wetzel S. A. Adler-Moore J. P. Antimicrobial activity of AmBisome and non-liposomal amphotericin B following uptake of Candida glabrata by murine epidermal Langerhans cells. Med. Mycol. 36 1998 135 141","journal-title":"Med. Mycol."},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.7326\/0003-4819-108-1-88","article-title":"Hepatic candidiasis in cancer patients: the evolving picture of the syndrome.","volume":"108","author":"Thaler M.","year":"1988","unstructured":"Thaler M. Pastakia B. Shawker T. H. O'Leary T. Pizzo P. A. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann. Intern. Med. 108 1988 88 100","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_1_36_2","first-page":"577","article-title":"Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.","volume":"12","author":"Tollemar J.","year":"1993","unstructured":"Tollemar J. Ringd\u00e9n O. Andersson S. Sundberg B. Ljungman P. Tyden G. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 12 1993 577 582","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00007890-199501150-00009","article-title":"Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients.","volume":"59","author":"Tollemar J.","year":"1995","unstructured":"Tollemar J. H\u00f6ckerstedt K. Ericzon B.-G. Jalanko H. Ringd\u00e9n O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 59 1995 45 50","journal-title":"Transplantation"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.5.1169-1175.1998"},{"key":"e_1_3_1_39_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/jac\/32.5.723","article-title":"Efficacies of amphotericin B-deoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice.","volume":"32","author":"van Etten E. W. M.","year":"1993","unstructured":"van Etten E. W. M. van Den Heuvel-De Groot C. Bakker-Woudenberg I. A. J. M. Efficacies of amphotericin B-deoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J. Antimicrob. Chemother. 32 1993 723 739","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1086\/516480"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2391"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/516353"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401004"},{"key":"e_1_3_1_44_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/00362178185380071","article-title":"Adoptive transfer of immunity to Histoplasma capsulatum in athymic nude mice.","volume":"19","author":"Williams D. M.","year":"1981","unstructured":"Williams D. M. Graybill J. R. Drutz D. J. Adoptive transfer of immunity to Histoplasma capsulatum in athymic nude mice. Sabouraudia 19 1981 39 48","journal-title":"Sabouraudia"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01229.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.9.2327-2332.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.9.2327-2332.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:46:35Z","timestamp":1645461995000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.9.2327-2332.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["10.1128\/AAC.44.9.2327-2332.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.9.2327-2332.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9]]},"assertion":[{"value":"2000-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-05-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}